Publication
Generative AI: A global guide to key IP considerations
Artificial intelligence (AI) raises many intellectual property (IP) issues.
Authors:
Global | Publication | 八月 2024
The rapid convergence of digital technologies with healthcare over the past five years (even prior to the COVID-19 pandemic) has transformed how healthcare is delivered to the masses. The promise of digital technologies continues to transform the healthcare delivery model from a traditional model based on a “one-size-fits-all” practice of medicine that was characterized by a provider-centric approach with information silos, to a new model that is focused on patient-centric treatment personalization with high data accessibility and utilization.
Read the full International Comparative Legal Guide.
On February 27, 2024, Turkish Pharmaceuticals and Medical Devices Authority has revised the Guideline on Good Distribution Practice (GDP) Audits, mandating that pharmaceutical businesses with permits undergo inspections to ensure compliance with GDP standards. Identified deficiencies must be remedied within a specified period, with evidence submitted to Authority. Moreover, routine controls by Provincial/District Health Directorates will document deficiencies, requiring businesses to address them within 15 days and submit proof of compliance to Authority.
The Regulation on the Importation of Medical Diagnostic Kits was repealed according to an announcement by the Turkish Ministry of Trade. This regulation, which previously governed the importation procedures and standards for medical diagnostic kits, was officially repealed on May 15, 2024, signifying a change in the regulatory approach to these medical devices.
Publication
Artificial intelligence (AI) raises many intellectual property (IP) issues.
Publication
We are delighted to announce that Al Hounsell, Director of Strategic Innovation & Legal Design based in our Toronto office, has been named 'Innovative Leader of the Year' at the International Legal Technology Association (ILTA) Awards.
Publication
After a lacklustre finish to 2022 when compared to the vintage year for M&A that was 2021, dealmakers expected 2023 to see the market continue to cool in most sectors, in response to the economic headwinds of rising inflation (with its corresponding impact on financing costs), declining market valuations, tightening regulatory scrutiny and increasing geopolitical tensions.
Subscribe and stay up to date with the latest legal news, information and events . . .
© Norton Rose Fulbright LLP 2023